Eli Lilly and Company (LLY) Unveils $5B Virginia Facility to Ramp Up Bioconjugate and Monoclonal Antibody Production

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Eli Lilly and Company is one of them.

Eli Lilly and Company (NYSE:LLY) tops our list for being one of the best pharmaceutical stocks. It is the Indianapolis-based pharmaceutical giant and is accelerating its dominance in obesity treatments while expanding its global footprint and manufacturing capacity.

The company’s obesity drug franchise, led by Mounjaro (tirzepatide), has scaled rapidly beyond the U.S. to Europe, Asia, the Middle East, and most recently Mexico, Brazil, India, and China. By leveraging partnerships with digital health and e-commerce platforms like Alibaba and JD.com, LLY has strengthened supply reliability and patient access, distinguishing itself from rival Novo Nordisk’s rollout hurdles.

This month, new clinical trial data boosted Eli Lilly and Company (NYSE:LLY)’s pipeline prospects. Orforglipron, its oral GLP-1 agonist, outperformed Novo Nordisk’s Rybelsus in blood sugar control and weight loss for type 2 diabetes patients.

Alongside drug innovation, the corporation is investing heavily in manufacturing capacity. The business announced a $5 billion facility near Richmond, Virginia, focused on bioconjugates and monoclonal antibodies, with significant economic impact expected. This is part of a broader $27 billion plan for four U.S. plants, reinforcing its push into next-generation oncology and autoimmune therapies.

The pipeline continues to advance across other areas as well. Alzheimer’s drug donanemab (Kisunla) recently received an FDA-approved dosing schedule and a positive nod from European regulators, while acquisitions like the $1.3 billion Verve Therapeutics deal strengthen the firm’s innovation engine.

On pricing, Eli Lilly and Company (NYSE:LLY) introduced a flat-rate $499 monthly model for Zepbound, improving affordability. U.S. policy shifts could further boost demand, with Medicaid coverage for GLP-1 weight-loss drugs set for 2026 and Medicare in 2027.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.